Biotech Daily Home

Biotech Daily covers the major announcements from more than 130 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A1080 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here



Latest News !

Dr Boreham's Crucible - Probiotec

Rhythm Bio $9m IPO For Bowel Cancer Blood Test 

Telix $50m IPO Up 25% For Molecular Targeted Cancer Radiation 

Living Cell Tumbles 89% On NTCell Parkinson's Results

Biotech Daily 12th Birthday Editorial

Biotech Daily Editorial - Selective Briefings 

Biotech Revenue Up 194% In 8 Years To $1.4b

4-Year Data Backs Prota, MCRI Peanut Immunotherapy

WEHI $405m+ Canada Venetoclax For Cancer Deal

10-Year BDI-40 Up 80%, ASX200 Down 9% Big Caps Up 270%

Novartis Buys Spinifex For $916m



November BDI-40 Up 1%, ASX Up 1%
Big Caps Up 3%, NBI Up 0.6%

Avita Up 83%, Compumedics 34%; Living Cell Down 85%, Viralytics 21%

Dec 1, 2017

Summer’s here and the time is right for the biotechnology sector – and the Big Caps continue to set new records (see charts below).
The Biotech Daily Top 40 Index (BDI-40) improved 1.2 percent in November, slightly ahead of the ASX200, which was up 1.0 percent, consolidating the Spring gains and recovering from earlier falls by Sirtex and Mesoblast.
Most of the BDI-20 companies were up, while the Second 20 lost ground.
Eighteen of the BDI-40 companies (not including Cochlear, CSL and Resmed) were up, 20 fell and two were unchanged.
Eleven climbed more than 10 percent, of which five were up by more than 20 percent and eight fell by more than 10 percent, with three down by more than 20 percent.
Avita was the best, recovering 93.3 percent to $66 million, but still $20 million below its market capitalization 12 months ago. Compumedics rebounded 33.9 percent to $75 million, followed by Impedimed also in recovery up 31.9 percent, Psivida (26.2%), Admedus (23.3%), Orthocell (16.7%), Clinuvel (15.0%), Polynovo (14.8%), Pro Medicus (12.7%) and Oncosil (10.6%).
Living Cell led the falls, down 85.1 percent to $17 million following non-significant results for its NTCell for Parkinson’s disease. Viralytics eased 21.2 percent to $145 million, followed by Genetic Signatures (20.5%), LBT (18.2%), Dimerix (17.6%), Nanosonics (15.4%), Uscom (15.0%), Cellmid (13.0%), Actinogen (12.5%) and Bionomics (11.9%).
The three Big Caps of Cochlear, CSL and Resmed hit record highs, again, at the end of November, up a collective 3.2 percent for the month (and 44.3 percent for the year to November 30), with Resmed up 3.7 percent to $15,976 million, CSL up 3.1 percent to $64,828 million and Cochlear up 2.7 percent to $10,400 million.
Outside the BDI-40, Anatara was up 12.8 percent for the month and 57.1 percent to a high of $88 million, Probiotec climbed 53.6 percent to $43 million and Noxopharm was up 210 percent in 12 months to $52 million.
Cannabis Corner’s 13 listed medical marijuana companies climbed 39.1 percent in November with stand-outs from Cann Group up 72.0 percent to $227 million, Hydroponics (160.0%), Zelda (106.5%), Auscann (50.0%) and MGC (47.1%).
In the US, Redhill lost 29.0 percent to $142 million on a discounted capital raise, Queensland’s Protagonist jumped 60.9 percent to $531 million and Aviragen (Biota) struggled up 9.7 percent to $34 million, with the Nasdaq Biotechnology Index up 0.55 percent for the month and 5.0 percent for the year.
Telix has listed on the ASX with phase III cancer imaging and phase II treatment trials and will replace Admedus in the Top 20, which joins Optiscan returning to the Second 20, proving, again, that what goes down can come up. Living Cell and Cellmid move to the Third 20.
BDI-40 v S&P ASX200 Jun 30, 2006 to Nov 30, 2017 
BDI-40 v S&P ASX200 Nov 30, 2016 to Nov 30, 2017 
Big Caps (Cochlear, CSL, Resmed) Year To Nov 30, 2017


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At Nov 30, 2017


* Biotech Daily editor, David Langsam, owns shares in Acrux, Benitec, Mesoblast, Nanosonics, Optiscan, Telix
   and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: